Coherent Market Insights (CMI) stated that by the end of 2028, the global interventional pulmonology market will exceed US$5.1075 billion at a compound annual growth rate of 5.4%

2021-12-15 00:23:27 By : Mr. Wynn Lee

Seattle, November 18, 2021 (GLOBE NEWSWIRE) - According to data from Coherent Market Insights, the global interventional pulmonology market in 2021 is estimated to be worth US$3.5353 billion, and is expected to grow at a compound annual growth rate of 5.4% during the forecast period (2021-2028) ).

The main trends and analysis of the global interventional pulmonology market:

It is expected that during the forecast period, the rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary disease and lung cancer will promote the growth of the global interventional pulmonology market. For example, according to an article published in the "Translational Lung Cancer Research" in May 2019, there were an estimated 733,000 new lung cancer cases and 610,000 deaths in China in 2015.

As the major players in the market focus on growth strategies, such as acquisitions, which are expected to drive market growth during the forecast period, the global interventional pulmonology market is expected to grow at a compound annual growth rate of 5.4% during the forecast period. For example, after the two companies signed the final agreement, Olympus completed the acquisition of Veran Medical Technologies, Inc. (VMT) in December 2020. Veran Medical Technologies, Inc. (VMT) specializes in interventional lung diseases. Leading supplier of advanced medical equipment. Through the acquisition of Olympus Americas (OCA), a subsidiary of Olympus, Olympus has acquired VMT's global sales network, marketing, manufacturing, R&D and other functions to expand Olympus respiratory products combination.

Request a sample copy of this report @

Among product types, the bronchoscopy segment is expected to dominate the global interventional pulmonology market during the forecast period. It is expected that increased research and development of robotic bronchoscopy will drive the growth of this segment of the market during the forecast period. For example, in January 2020, researchers at Fox Chase Cancer Center found that robotic bronchoscopy technology is safe, feasible, and reliable for realizing lung cancer diagnosis. In addition, Fox Chase is one of the first cancer centers in the United States to obtain this technology, and it is sold on the Monarch platform. Robotic bronchoscopy is a diagnostic technique used to look inside the lungs and obtain tissue samples for biopsy.

By region, as major players in the market focus on US Food and Drug Administration (FDA) approvals, North America is expected to dominate the global interventional pulmonology market during the forecast period. For example, in October 2018, the commercial medical technology company Pulmonx Corp. announced that the US FDA has approved the Zephyr endobronchial valve system for the treatment of patients with severe emphysema. The Zephyr valve is the first minimally invasive device approved in the United States for the treatment of patients with severe emphysema, a progressive and life-threatening chronic obstructive pulmonary disease (COPD).

Major players operating in the global interventional pulmonology market include Boston Scientific, Olympus, Fujifilm, Becton, Dickinson and Company, Smiths Group plc., Cook Medical, Vygon, PENTAX Medical, Clarus Medical LLC, HUGER Medical Instrument Co., Ltd ., Richard Wolf Corporation, Karl Storz, Taewoong Medical Co., Ltd, and ELLA – CS, sro

Buy this research report now @

The global interventional pulmonology market, by product type:

The global interventional pulmonology market, by indication:

The global interventional pulmonology market, by end user:

The global interventional pulmonology market by region:

The brain cancer treatment market, by indication (glioblastoma, meningioma, pituitary tumor, etc.), treatment type (targeted therapy, chemotherapy, immunotherapy, etc.), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), And by region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)-size, share, prospect and opportunity analysis, 2021-2028

Castration-resistant prostate cancer market, by treatment type (hormone therapy, immunotherapy and chemotherapy), by drug category (anti-tumor, non-steroidal antiandrogens, corticosteroids, microtubule inhibitors, etc.), and by route of administration ( Oral and injection), by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) and by region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)-size, share, prospects and opportunity analysis, 2021-2028

Coherent Market Insights is a global market intelligence and consulting organization focused on helping many of our clients achieve transformational growth by helping them make key business decisions. We are headquartered in India, with sales offices in Global Financial Capital in the United States, and sales consultants in the United Kingdom and Japan. Our customer base includes participants from various business verticals in more than 57 countries/regions around the world.

Investors in Nvidia (NASDAQ: NVDA) stock seem to be unable to rest. Reason: Once again, Wall Street seems to be just looking for a cheaper way to deal with the global semiconductor shortage than buying Nvidia stock. According to report, this growth rate is almost twice the 6% growth rate previously predicted by Citigroup. The problem is that when interpreting these data, Citi chose to highly evaluate its potential to increase the earnings of AMD and Intel—making these two chip companies exceed expectations in the fourth quarter.

Microsoft (NASDAQ: MSFT) shares closed down 3.3% on Tuesday after the US Department of Labor reported that producer price inflation in November hit a record high, up 9.6% year-on-year. The news came before the 6.8% increase in consumer prices announced yesterday-the fastest price increase in 40 years. When Bloomberg reported that Microsoft's stock price fell, it drew clues to Microsoft's stock price weakness directly from the inflation data. Think about it this way: Currently, analysts tracking Microsoft stock predict that the company's annual revenue will grow by about 15% in the next five years.

At a basic level, all companies have the same goals-only some companies are good at it.

On Tuesday, cloud software companies Datadog (Nasdaq: DDOG), Zscaler (Nasdaq: ZS) and Cloudflare (NYSE: NET) fell. This is another difficult issue for technology stocks. day. In a wide-ranging report from the bank, Sterling Auty, a software analyst at JPMorgan Chase, issued a new appeal to the entire industry.

Investors are reminded to pay attention to several risk factors that need to be considered for this investment.

Our appeal from Stifel that day believes that the Fed is working hard to create a bubble of the century. This is what happened before.

(Bloomberg)-Former US Secretary of the Treasury Lawrence Summers warned that retail purchases and enthusiastic investors have pushed up the risk of "spontaneous financial market contraction." Can Paradise Indoor Farm reach the height of a skyscraper? China is building the world’s largest national park system. Boris Johnson’s angry members of Congress worry that his next mistake may be fatal, with "a lot of euphoria," Summers said.

Making progress in promoting the transition to a hydrogen economy, Plug Power (NASDAQ: PLUG) today announced the signing of a long-term supply and logistics agreement. However, considering that the details of the partnership are quite small, investors are not impressed. As of 12:14 pm Eastern Time, Plug Power's stock price has fallen 6.2%. Although Plug Power initially made money by providing fuel cell systems, the company has articulated its long-term vision of diversifying its business by producing green hydrogen.

The Supreme Court will not block the authorization of New York's healthcare vaccines, Apple is preparing to become the first company with a market value of $3 trillion, MGM Resorts selling Mirage Hotel to Hard Rock, and other news to start a new day.

Is the bear finally waking up from hibernation? Goldman Sachs said it was not so fast. Volatility has recently dominated Wall Street, leading some to conclude that those with a more pessimistic outlook have been proven correct, but the company believes that the stock market can still climb. According to David Costin, head of US equity strategy at Goldman Sachs, the S&P 500 index may reach 5,100 points next year. If the index finally reaches this target, it will reflect a 10% return. "If you are looking for a good

Sunrun (NASDAQ: RUN) shares fell on Tuesday after a regulatory proposal threatened a slowdown in the growth of the solar industry. As of 3:25 pm Eastern Time, Sunrun's stock price has fallen by more than 13%. The proposed changes to California's net energy metering program may significantly increase consumer costs and eliminate "tens of thousands of jobs." Fenster said in a press release that it “represents the worst aspect of California politics, while ignoring what voters want—innovation, control, and quick solutions—but supporting failed and boring incumbents. " (NYSE: CRM), a customer relationship management software company, fell sharply on Tuesday. As of this writing, the Nasdaq Composite Index, which is dominated by technology stocks, is down more than 2%. Salesforce's decline came shortly after the company announced its strong third-quarter results, but its guidance for the fourth quarter of fiscal year 2022 was mixed.

In the long run, investing in emerging technologies can bring substantial returns to investors.

The CEO made a big bet on Bitcoin. But he is not alone.

In this article, we will discuss the 10 best Jim Kramer stocks to watch in December. If you want to skip our detailed analysis of these stocks, please go directly to the 5 Jim Cramer stocks to watch in December. Jim Cramer, CNBC's Mad Money host, is one of the most watched financial experts in the market today. [...]

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora") is a Canadian company that defines the future of global cannabinoids, and 22nd Century Group, Inc. (NASDAQ: (Stock code: XXII) ("22nd Century") together announced today that a tripartite non-exclusive agreement licenses biosynthetic intellectual property rights to Cronos Group Inc. (NASDAQ: CRON) (TSX code: CRON) ("Cronos Group"), aims to assist in the advancement of biosynthetic research and development of cannabinoids.

The share prices of Roku (NASDAQ: ROKU), Snowflake (NYSE: SNOW) and DraftKings (NASDAQ: DKNG) all fell more than 6%, and then rebounded slightly. First of all, they are both very high multiple growth stocks. Traders seem to worry that at the Fed meeting this week, officials may decide to accelerate the pace of financial tightening, which may damage these types of stocks in terms of finances and valuation. Fed officials will meet on Tuesday and Wednesday and may discuss a faster reduction in bond purchases, which reflects Fed Chairman Jerome Powell’s comments earlier this month.

(Bloomberg)-Microsoft fell on Tuesday, and the software company led the decline among large Internet and technology stocks. Most of the reading comes from Bloomberg. Zero taxes, golf and beach villas have created a crypto island paradise. Can indoor farms reach the height of skyscrapers? China is building the world's largest national park system Boris Johnson's angry congressmen worried that his next mistake could be fatal. The stock fell 3.3%, the biggest one-day percentage drop since September. One day's fall erased more

The company has just entered the third day of open market trading and is experiencing volatility.

Ford Motor (Stock Code: F) shares more than doubled this year, and its executive chairman William Clayford Jr. just disclosed the acquisition of a large number of shares in the auto giant. As of Tuesday's close, Ford Motor's stock price has soared 128% so far this year. As we all know, Chairman Bill Ford purchased 412,500 shares at a price of US$8.5 million on December 10, at an average price of US$20.62 per share. According to a form he filed with the Securities and Exchange Commission on Tuesday, Bill Ford purchased these shares through a trust that now owns 4 million Ford shares.